Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ocugen Inc
(NQ:
OCGN
)
0.9110
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen Inc
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024
October 28, 2024
From
Ocugen
Via
GlobeNewswire
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
October 22, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results
October 17, 2024
From
Ocugen
Via
GlobeNewswire
Peering Into Ocugen's Recent Short Interest
August 09, 2024
Via
Benzinga
Why Ocugen (OCGN) Stock Is Falling
August 01, 2024
Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering.
Via
Benzinga
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit
October 10, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
October 09, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa
October 02, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
From
Ocugen
Via
GlobeNewswire
Kaskela Law LLC Announces Shareholder Investigation of Ocugen, Inc. (NASDAQ: OCGN) and Encourages Investors to Contact the Firm
September 17, 2024
From
Kaskela Law LLC
Via
Business Wire
Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop
September 09, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit
September 05, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
August 28, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
August 26, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen (OCGN) Q2 2024 Earnings Call Transcript
August 08, 2024
OCGN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Ocugen Provides Business Update with Second Quarter 2024 Financial Results
August 08, 2024
From
Ocugen
Via
GlobeNewswire
InvestorNewsBreaks – Ocugen Inc. (NASDAQ: OCGN) Closes on $35M Public Offering
August 06, 2024
Via
Investor Brand Network
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
August 05, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
August 02, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
July 31, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
July 29, 2024
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
July 25, 2024
From
Ocugen
Via
GlobeNewswire
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
July 11, 2024
These two stocks could have vastly different long-term performances.
Via
The Motley Fool
3 Penny Stocks That Could Turn $10K Into $100K in 3 Years
July 06, 2024
Discover three high-potential penny stocks that could derive 10X returns in biotechnology, silver and oil and gas storage and transportation.
Via
InvestorPlace
7 A-Rated Penny Stocks to Beat June Gloom
June 24, 2024
Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month.
Via
InvestorPlace
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
June 21, 2024
From
Ocugen
Via
GlobeNewswire
3 Penny Stocks Set to Make New Millionaires in 2024
June 20, 2024
Explore the best penny stocks to buy and their progressive fundamentals in biotechnology, healthcare, and electrical components.
Via
InvestorPlace
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
June 20, 2024
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.